Drugs / IVT PCV-25
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05540028 | Sep 2022 → Jul 2023 | — | Inventprise Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVT PCV-25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05540028 ↗ |
| Known as | PCV25 | “IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine (PCV25) designed to prevent invasive pneumococcal disease from the serotypes predominant in children, particularly in...” PMID 41576705 ↗ Jan 2026 |
| Modality | Vaccine | “25-valent pneumococcal conjugate vaccine” NCT05540028 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT05540028 ↗ |